Skip to main content


We're creating a new version of this page. See preview

  • Review
  • Open Access

Mineralocorticoid receptor antagonists in dialysis patients

  • 1,
  • 1,
  • 1,
  • 1 and
  • 1Email author
Renal Replacement Therapy20162:64

  • Received: 1 September 2016
  • Accepted: 2 November 2016
  • Published:


Mineralocorticoid receptor (MR) antagonists are known to have beneficial effects in patients with cardiovascular disease without renal failure. However, there have been few published studies on the effectiveness of MR antagonists in dialysis patients, and most of the studies were small-sized. The present review focuses on the effectiveness of MR antagonists and the risk of hyperkalemia in dialysis patients. Severe hyperkalemia due to treatment with MR antagonists in dialysis patients is not common, particularly in peritoneal dialysis (PD) patients, and the prospect of cardioprotective effects has been hopeful in both hemodialysis (HD) and PD patients. Further studies are required to establish optimal protocols for the use of MR antagonists in these patients without adverse effects.


  • Mineralocorticoid receptor antagonist
  • Cardiovascular disease
  • Dialysis patients
  • Aldosterone
  • Peritoneal fibrosis


The number of patients with end-stage renal disease (ESRD) who are undergoing dialysis is increasing. Although dialysis treatment techniques have improved, cardiovascular mortality in dialysis patients is still 10 to 20 times higher than in the general population [1]. In addition, data from the Japanese Society of Dialysis at the end of 2013 showed that heart failure constituted 26.8% of the main causes of death in dialysis patients in Japan [2]. Mineralocorticoid receptor (MR) antagonists have been reported to improve the prognosis of chronic heart failure [3, 4], heart failure after acute myocardial infarction [5], and left ventricular (LV) hypertrophy [6] among patients without renal failure. In contrast in the patients with advanced renal failure, MR antagonists have not been recommended because of concern of causing hyperkalemia [7, 8]. This review article summarizes the beneficial effects of MR antagonists for patients with cardiovascular disease as discussed in recent reports, and evaluates the efficacy of treatment with MR antagonists and risk of hyperkalemia in patients receiving hemodialysis (HD) and peritoneal dialysis (PD).


Since 1960 spironolactone has been used as a potassium-sparing diuretic to control edema, hypertension, ascites of cirrhosis, and primary aldosteronism by inhibiting the mineralocorticoid (aldosterone) receptor [9]. Aldosterone acts on epithelial cells such as renal collecting duct tubules and intestinal mucosa, and controls the extracellular fluid volume by increasing sodium reabsorption [1012]. Because aldosterone is located in the most downstream area of the renin-angiotensin-aldosterone system, it has been thought to indirectly cause cardiovascular disorders through the increase of extracellular fluid volume and hypertension [13]. In large cohort studies, MR antagonists showed reduction of mortality in the patients with severe heart failure and acute myocardial infarction complicated by left ventricular dysfunction. These effects were suggested not to be related to hemodynamic effects. [3, 5]. Patients with primary aldosteronism are known to have a higher incidence of LV hypertrophy, stroke, and microalbuminuria than patients with essential hypertension. In addition, the occurrence rate of LV hypertrophy is higher in patients with primary aldosteronism than in patients with other types of secondary hypertension [14]. These reports suggest that aldosterone can cause direct organ damage independent of blood pressure.

The MR has been shown to be expressed in many organs such as the brain, heart, and blood vessels; and the MR produces a variety of actions in each organ (Table 1) [1517]. The effects of aldosterone on the cardiovascular system have been widely reported in relation to vascular remodeling [18, 19], endothelial dysfunction [20, 21], increased oxidative stress [22], vascular inflammation promotion [23], and cardiomyocyte hypertrophy [24], either by aldosterone alone or through cooperative action with angiotensin II or salt intake [25, 26].
Table 1

Effects of aldosterone in associated disorders [25]

Effects of aldosterone

Myocardial fibrosis and remodeling

Vascular injury and fibrosis

Reduced vascular compliance

Impaired baroreceptor function

Endothelial dysfunction

Catecholamine potentiation

Ventricular arrhythmias

Progressive renal disease

K+ and Mg2+ loss

Sodium reabsorption and water retention

Prothrombotic effects (Increasing PAI-1)

Aldosterone-associated disorders


Heart failure and cardiac hypertrophy


Ischemia and arteriosclerosis

End-stage renal disease

Peritoneal fibrosis

PAI-1 plasminogen activator inhibitor-1

In the heart, aldosterone has been reported to play a role in inducing cardiac hypertrophy. In particular, aldosterone with salt-loading induces cardiac hypertrophy associated with fibrosis, which is attenuated by MR blockade [24, 27]. Aldosterone and high salt administration for 4 weeks was observed to induce upregulation for nuclear factor (NF)-κB, nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase), and oxidative stress, leading to increases in monocyte chemoattractant protein-1 (MCP-1), intracellular adhesion molecule 1 (ICAM1), tumor necrosis factor alpha (TNF-α), and macrophage infiltration in the perivascular area of the intramyocardial coronary arteries and at sites of myocardial injury [22].

The MR, which is expressed not only in the endothelial cells but also in the vascular smooth muscle cells [28], has been reported to be involved in vascular injury. For vascular endothelial cells, aldosterone and the MR are related to endothelial dysfunction, coagulation, inflammation and fibrosis, nitric oxide (NO) synthesis, and oxidative stress [29]. Endothelial dysfunction is one of the factors of atherosclerosis. Aldosterone exacerbates neointimal thickening after balloon injury and is blocked by spironolactone [30]. Aldosterone has been reported to induce a prothrombotic condition by upregulation of plasminogen activator inhibitor-1 [31]. Aldosterone was also shown to induce inflammation through upregulation of oxidative stress, which was ameliorated by spironolactone [32]. Aldosterone was found to downregulate NO production in vascular endothelial cells, resulting in inhibition of vascular relaxation, which was attenuated with MR blockade [33, 34]. Interestingly, in vivo studies in rabbits with high cholesterol diets showed that eplerenone reduced superoxide generation and improved endothelial function [35]. Also, in monkeys receiving high cholesterol diets, eplerenone improved endothelium-dependent relaxation [36]. In the recent report, MR in endothelial cells was shown to play a role in regulating endothelial function in hypertension using the mice with MR specifically deleted in the endothelial cells [37].

In vascular smooth muscle cells, aldosterone induced proliferation [38] and oxidative stress [39]. Aldosterone activated the mitogen-activated protein (MAP) kinases and NADPH oxidase through c-Src, leading to damage of vascular smooth muscle cells [39]. In addition, spironolactone inhibited the progression of aortic calcification in rats with adenine-induced chronic kidney disease (CKD) because of suppression of osteogenic transition and apoptosis in the aorta [40]. Recently, arterial stiffness was shown to be modulated by MR activation in vascular smooth muscle cells using a mouse with conditional inactivation of MR in these cells [41]. The main functions of aldosterone are summarized in Table 1.

Effects of the MR antagonists in hemodialysis patients

There have been many reports about the cardioprotective effects of MR antagonists and the concomitant risk of hyperkalemia in HD patients (Table 2).
Table 2

Effects of MR antagonists in hemodialysis patients


Number of patients

Administration period

Study duration


Change of plasma potassium

Papadimitriou et al. [42]

9 HD patients

Spironolactone 300 mg/day

3 weeks

Blood pressure remained unchanged.

Plasma potassium levels increased.

Saudan et al. [43]

14 HD patients

Spironolactone 12.5 mg × 3/week for 2 weeks; then increased 25 mg × 3/week for 2 weeks

4 weeks


Serum potassium levels did not differ between spironolactone group and control group (4.9 ± 0.7 vs. 4.9 ± 0.3 mEq/l, N.S.).

Hussain et al. [44]

15 HD patients

Spironolactone 25 mg/day

28 days


4.6 ± 0.6 at baseline 4.9 ± 0.9 mEq/l at study completion (P = 0.14).

One patient developed hyperkalemia (K = 7.6 mEq/l).

Nitta et al. [55]

5 HD patients

Spironolactone 50 mg/day

3.1 ± 1.2 years

ACI decreased.

Plasma osteopontin decreased.


Gross et al. [45]

8 HD patients

Spironolactone 50 mg × 2/day

2 weeks

Systolic blood pressure reduced.

Plasma aldosterone and renin activity were not significantly different from placebo group.

Spironolactone group 5.0 ± 0.8 versus placebo group 4.7 ± 0.5 mEq/l (P > 0.05).

Taheri et al. [48]

8 HD patients with heart failure and LVEF ≤45%

Spironolactone 25 mg × 3/week

6 months

LVEF and LV mass improved.

Potassium level increased by 21% in the spironolactone group.

McGill et al. [49]

13 HD patients

Spironolactone 25 mg/day

9 months

Cardiac MRI was not improved..

There was no incidence of hyperkalemia (K > 6.0 mEq/l).

Matsumoto et al. [53]

61 HD patients

Spironolactone 25 mg/day

6 months


Potassium levels were 4.96 ± 0.72 at baseline and 5.18 ± 0.72 mEq/l at 6 months (P < 0.05). No patients developed over 6.8 mEq/l.

Vukusich et al. [56]

33 HD patients

Spironolactone 50 mg × 3/week

2 years

CIMT decreased.

No patients developed hyperkalemia, but the potassium levels in the spironolactone group increased (P < 0.001).

Shavit et al. [46]

8 HD patients

Eplerenone 25 mg × 2/day

4 weeks

Systolic blood pressure reduced.

Plasma potassium concentration was 4.67 ± 0.2 at baseline and 4.86 ± 0.38 mEq/l after 4 weeks (P = 0.48).

Flevari et al. [50]

14 HD patients

Spironolactone 25 mg × 3/week

4 months

Blood pressure controlled, the reactive hyperemia and heart rate variability improved. LV dimensions and mass were not improved.

The potassium level increased from 4.4 ± 0.2 to 5.5 ± 0.3 mEq/l (P < 0.05). Two patients took cation exchange resin due to hyperkalemia (K > 6 mEq/l).

Matsumoto et al. [52]

157 HD patients

Spironolactone 25 mg/day

3 years

Death or hospitalization for CCV events and all-cause mortality reduced.

Potassium level was 5.16 at baseline vs. 5.14 mEq/l after 3 years. Three patients discontinued in spironolactone because of hyperkalemia.

Walsh et al. [47]

77 HD patients

Eplerenone 50 mg/day

13 weeks

Discontinuation of the drug because of hyperkalemia or hypotension was not different.

Nine patients developed hyperkalemia (K > 6.5 mEq/l) in the eplerenone group compared with two patients in the placebo group.

Feniman-De-Stefano et al. [51]

8 HD patients

Spironolactone 25 mg/day

6 months

LV mass index decreased.

There was no significant difference between spironolactone and placebo groups (5.0 ± 0.31 in the spironolactone group vs 4.9 ± 0.24 mEq/l in the control group, P = 0.568).

Lin et al. [54]

125 HD + PD patients

Spironolactone 25 mg/day

2 years

CCV events and the rates of death from all causes reduced. LV mass index, LVEF, and FMD were improved.

Potassium level rose from 4.12 ± 0.42 to 5.32 ± 0.68 mEq/l after 2 years, but was not significantly elevated compared with the control group (P = 0.13).

ACI aortic calcification index, CCV cardiovascular and cerebrovascular, CIMT carotid intima-media thickness, EF ejection fraction, ESRD end-stage renal disease, FMD flow-mediated dilation, HD hemodialysis, LV left ventricular, MR mineralocorticoid receptor, MRI magnetic resonance imaging, PD peritoneal dialysis, N.S. not significant

Risk of hyperkalemia

In a 1983 study, spironolactone at 300 mg/day was administered to 9 HD patients for 3 weeks. At the end of the study, plasma potassium levels were significantly increased [42]. However, the patients in this study had received a higher dose of spironolactone than that used commonly. Saudan et al. [43] reported 14 HD patients who received low-dose spironolactone at 12.5 mg × 3/week after dialysis sessions for 2 weeks. Then, the dose was increased to 25 mg × 3/week and continued for 2 weeks in comparison with 21 HD control patients. The serum potassium levels did not significantly differ between the two groups (4.9 ± 0.7 in the spironolactone group and 4.9 ± 0.3 mEq/l in the control group). Hussain et al. [44] reported that 15 HD patients with serum potassium levels <5.6 mEq/l were treated with spironolactone at 25 mg/day for 28 days. The mean potassium levels did not significantly increase (before - 4.6 ± 0.6 mEq/l; after - 4.9 ± 0.9 mEq/l, P = 0.14); however, the potassium level of one patient rose to 7.6 mEq/l, and this patient was dropped from the study. Gross et al. [45] reported a randomized, double-blinded, placebo-controlled study in which 8 HD patients were administered spironolactone 50 mg × 2/day or placebo for 2 weeks; after a 3-week washout period, the patients crossed over in the treatment arms for 2 more weeks. After administration of spironolactone for 2 weeks, systolic blood pressure was significantly reduced from 142.0 ± 19.6 to 131.4 ± 18.2 mmHg (P < 0.05). In contrast, plasma potassium levels were not different between spironolactone treatment and placebo groups (5.0 ± 0.8 vs 4.7 ± 0.5 mEq/l, P = n.s.). Similar trials were reported using eplerenone, another MR antagonist. Shavit et al. [46] treated 8 HD patients with low-dose eplerenone at 25 mg × 2/day for 4 weeks. After 4 weeks, the systolic blood pressure was reduced from 166 ± 14 to 153 ± 10 mmHg (P < 0.05); however, there was no significant change in the potassium level (before - 4.67 ± 0.2 mEq/l, after - 4.86 ± 0.38 mEq/l, P = 0.48). In addition, Walsh et al. [47] conducted a randomized, double-blinded, placebo-controlled study of 154 HD patients. In the study, 77 and 77 patients were treated with eplerenone 50 mg/day or placebo, respectively, and followed for 13 weeks. Nine patients developed hyperkalemia (K > 6.5 mEq/l) in the eplerenone group compared with two patients in the placebo group (relative risk, 4.5; 95% confidence interval, CI 1.0–20.2); however, there was no significant difference in the dropout rate from adverse events (hyperkalemia or hypotension) between the two groups.

Effects on cardiovascular disease

The effects of MR blockade on cardiac function in HD patients have also been reported. First, Taheri et al. [48] conducted a randomized, double-blinded, placebo-controlled study in 16 HD patients with heart failure and low LV ejection fraction (EF) ≤45%, who received spironolactone at 25 mg × 3/week (n = 8) or placebo (n = 8). After 6 months, the mean EF significantly increased in the spironolactone group compared with the placebo group (6.2 ± 1.64 vs. 0.83 ± 4.9%, P = 0.046), and the mean LV mass decreased in the spironolactone group compared with the placebo group (-8.4 ± 4.72 vs. 3 ± 7.97%, P = 0.021). The potassium level increased by 21% in the spironolactone group, but the incidence of hyperkalemia was not significantly increased. McGill et al. [49] conducted a small-sized study of 13 HD patients treated with spironolactone at 25 mg/day for 9 months and evaluated LV mass by cardiac magnetic resonance imaging. No improvements in LV mass were detected. Another research group reported a small-sized study with 14 HD patients without heart failure who received low-dose spironolactone at 25 mg × 3/week. After 4 months, blood pressure control, reactive hyperemia, and heart rate variability were significantly improved, while LV dimensions or mass were not improved [50]. Feniman-De-Stefano et al. [51] conducted a small-sized randomized, double-blinded, placebo-controlled study in which 17 HD patients were divided into 2 groups. Eight HD patients received spironolactone and 9 patients received placebo for 6 months; the spironolactone was administered at 12.5 mg/day for 1 week, after which the dose was increased to 25 mg/day. The LV mass index was significantly reduced from 77 ± 14.6 g/m2.7 to 69 ± 10.5 g/m2.7 (P = 0.039) in the spironolactone group, whereas in the placebo group there was an increase from 71 ± 14.2 to 74 ± 17.4 g/m2.7 (P > 0.05).

Matsumoto et al. [52] conducted a large-scale randomized trial in HD patients. These investigators performed a pilot study to evaluate the safety of spironolactone. Sixty-one HD patients received spironolactone at 25 mg/day for 6 months. The mean potassium level was significantly higher at the end of the study than at baseline, but no patients developed a potassium level >6.8 mEq/l [53]. Based on the safety of this pilot study, Matsumoto et al. [52] conducted a 3-year follow-up randomized trial. One hundred fifty-seven HD patients who received spironolactone at 25 mg/day were compared with 152 control patients. The composite rate of death or hospitalization due to cardiovascular and cerebrovascular (CCV) events during 3 years was 5.7% in the spironolactone group and 12.5% in the control group. Death from all causes was 6.4% in the spironolactone group and 19.7% in the control group. The average potassium level did not increase significantly; however, 3 patients in the spironolactone group discontinued the study because of developing hyperkalemia during the study. Lin et al. [54] also reported a multicenter, randomized, placebo-controlled study in which 125 HD + PD patients received spironolactone at 25 mg/day and 128 patients received placebo for 2 years. Death from CCV events occurred in 4.0% of the spironolactone group vs 11.7% in the control group. All-cause mortality was 9.6% in the spironolactone group and 19.5% in the control group. LV mass index, LVEF, and flow-mediated dilation were significantly improved from baseline in the spironolactone group but not in the control group. The potassium level rose from 4.12 ± 0.42 to 5.32 ± 0.68 mEq/l but was not significantly elevated compared with the control group. Three patients in the spironolactone group experienced an increase in their plasma potassium levels up to 6.0~6.5 mEq/l.

The effects of spironolactone on blood vessels have also been reported. Nitta et al. [55] reported a small study in which 5 HD patients received spironolactone for 3.1 ± 1.2 years and were evaluated for the aortic calcification index (ACI) by abdominal computed tomography scan. The mean ACI was significantly decreased from 27.0 ± 12.8 to 18.6 ± 11.8% (P = 0.003). Vukusich et al. [56] performed a randomized, double-blinded, placebo-controlled trial in 33 HD patients who received spironolactone at 50 mg × 3/week and in 33 HD control patients. After 2 years, carotid intima-media thickness significantly improved in the spironolactone group compared with the placebo group.

Taken together, hyperkalemia does not commonly occur in HD patients who receive treatment with MR antagonists; however, attention should be paid to serum potassium levels. Cardioprotective effects have been shown in many reports. Two reports described an improvement in mortality [52, 54]; therefore, MR antagonists hold promise for improving the prognosis in HD patients.

Effects of MR antagonists in peritoneal dialysis patients

Cardioprotective effects and risk of hyperkalemia in peritoneal dialysis patients

The number of reports on MR antagonists with respect to their cardioprotective effects and adverse effects in PD patients, summarized in Table 3, has been fewer than the number of reports in HD patients. In 2002, Hausmann et al. [57] first reported a 73-year-old patient on PD who received spironolactone at 25 mg/day, in whom the EF improved from 32 to 46% after 10 months. Taheri et al. [58] conducted a small-sized randomized, double-blinded, placebo-controlled study in which 18 PD patients with heart failure received spironolactone at 25 mg (n = 9) or placebo (n = 9) every other day for 6 months. The EF in the placebo group did not change (before - 33.3 ± 11.7 vs after - 34.2 ± 11.6, P = 0.363); however, the EF in the spironolactone group significantly improved (before - 25.7 ± 7.3 vs after - 33.3 ± 7.8, P = 0.002). Although there was no significant difference in the serum potassium level between the spironolactone and placebo groups, one patient in the spironolactone group developed hyperkalemia with K = 5.70 mEq/l. After the Taheri study, Yongsiri et al. [59] reported a small-sized, randomized, double-blinded, placebo-controlled, crossover study that focused on changes in potassium levels. Twenty-four PD patients with hypokalemia received spironolactone at 25 mg/day for 4 weeks. The serum potassium levels did not change significantly (4.23 ± 0.64 vs 3.90 ± 0.59 mEq/l in the patients who received spironolactone, P = 0.077), but one patient in the spironolactone group developed hyperkalemia with K = 5.6 mEq/l.
Table 3

Effects of MR antagonists in peritoneal dialysis patients


Number of patients

Administration period

Study duration


Change of plasma potassium

Hausmann et al. [57]

One PD patient

Spironolactone 25 mg/day

10 months

LVEF increased.

Potassium level was below 5.1 at pretreatment and below 5.5 mEq/l after spironolactone treatment.

Taheri et al. [58]

9 PD patients with heart failure

Spironolactone 25 mg every other day

6 months

LVEF increased.

There was no significantly difference between spironolactone and placebo groups (P > 0.05). One patient in the spironolactone group developed hyperkalemia (K = 5.70 mEq/l).

Ito et al. [60]

78 PD patients

Spironolactone 25 mg/day

2 years

LV mass index and LVEF improved.

Potassium levels were significantly higher in the spironolactone group after 6 and 12 months (P < 0.05).

Two patients in the spironolactone group developed hyperkalemia (K = 6.0 mEq/l), and one patient (K = 6.1 mEq/l) in the control group.

Yongsiri et al. [59]

24 PD patients with hypokalemia

Spironolactone 25 mg/day

4 weeks


Potassium levels 4.23 ± 0.64 at base line and 3.90 ± 0.59 mEq/l after 4 weeks (P = 0.077). One patient in the spironolactone group developed hyperkalemia (K = 5.6 mEq/l).

Yelken et al. [72]

23 PD patients

Spironolactone 25 mg/day

6 months

Dialysate CA125 increased.

Residual GFR declined.

Potassium level 4.3 ± 0.5 at baseline and 4.4 ± 0.6 mEq/l after 6 months (P = 0.488).

Vazquez-Rangel et al. [73]

9 PD patients

Spironolactone 25 mg/day

6 months

CD20 and collagen IV levels in peritoneal biopsy specimens decreased.

Potassium levels 4.8 ± 0.4 in the spironolactone group and 4.4 ± 0.5 mEq/l in the control group (P = 0.2).

CA125 cancer antigen 125, EF ejection fraction, GFR glomerular filtration rate, LV left ventricular, MR mineralocorticoid receptor, PD peritoneal dialysis

Because most of the studies on the effects of spironolactone in dialysis patients have been small-sized, we conducted a multicenter, open-label, prospective, randomized trial to investigate the add-on effects of MR antagonists in PD patients [60]. One hundred fifty-eight PD patients treated with an angiotensin-converting enzyme inhibitor or an angiotensin type 1 receptor antagonist were enrolled from 12 hospitals in the Tokai area in Japan. Seventy-eight PD patients received spironolactone at 25 mg/day for 2 years, and 80 patients as the control group did not receive spironolactone. The rate of change in the LV mass index and LVEF in the spironolactone group improved significantly compared with the control group (LV mass index - P = 0.01, EF - P = 0.02). In the present study, the effects of spironolactone were clearly shown in the males, whereas we could not show usefulness in the females because an insufficient number of females was enrolled. Serum potassium levels were significantly elevated in the spironolactone group at 6 months and 12 months after treatment with spironolactone. Only two patients in the spironolactone group developed hyperkalemia (maximum K level 6.0 mEq/l); on the other hand, one patient in the control group developed hyperkalemia (K level 6.2 mEq/l). There was no significant difference in the occurrence of hyperkalemia between the two groups (P = 0.62). Moreover, hypokalemia (potassium level < 3.0 mEq/l) occurred in 25% of the control group and 15.4% of the spironolactone group [60].

Protective effects on the peritoneal membrane in PD patients

Peritoneal membrane deterioration associated with peritoneal fibrosis and neoangiogenesis is one of the important problems for patients receiving long-term PD [61]. Peritoneal injury is caused by bioincompatible peritoneal dialysis solution [6264], peritonitis [6567], and uremia [68, 69]. MR antagonists have been reported to ameliorate peritoneal fibrosis in a rat peritonitis model [70, 71].

Two reports have discussed the effects of spironolactone on the peritoneal membrane in PD patients. Yelken et al. [72] reported 23 PD patients who received spironolactone at 25 mg/day for 6 months. After spironolactone administration, mean dialysate cancer antigen 125 significantly increased (P = 0.028), while the potassium level did not change significantly (4.3 ± 0.5 at baseline vs 4.4 ± 0.6 mEq/l after 6 months, P = 0.488). Vazquez-Rangel et al. [73] conducted a randomized, double-blinded, placebo-controlled study. Nine PD patients received spironolactone at 25 mg/day for 6 months and underwent peritoneal biopsies when the PD catheter was placed and at the conclusion of follow-up. Spironolactone decreased the CD20 and collagen IV levels in the peritoneal biopsy specimens in the patients who received spironolactone compared with the placebo group. There was no significant difference in the potassium level between the 2 groups. The effects of MR antagonists on the peritoneal membrane in PD are still obscure. Future studies are necessary to determine whether MR blockade is useful for ameliorating peritoneal damage in PD patients.

These reports indicate that the risk of severe hyperkalemia is not significantly increased in patients receiving MR treatment, and the cardioprotective effects produced by MR antagonists are promising in PD patients.


Recent evidence has suggested that administration of low-dose MR antagonists does not significantly elevate the risk of hyperkalemia, and that cardioprotective effectiveness is provided by MR antagonists in both HD and PD patients. Moreover, MR antagonists are expected to improve mortality in ESRD dialysis patients. Since most of the studies have been small size and used short observation periods, further large-scale clinical studies are required to establish the protocol for use of MR antagonists in dialysis patients.



Aortic calcification index


Cardiovascular and cerebrovascular


Chronic kidney disease


Ejection fraction


End-stage renal disease




Intracellular adhesion molecule 1


Left ventricular


Mitogen-activated protein


Monocyte chemoattractant protein-1


Mineralocorticoid receptor

NADPH oxidase: 

Nicotinamide adenine dinucleotide phosphate-oxidase


Nuclear factor


Nitric oxide


Peritoneal dialysis


Tumor necrosis factor alpha



Not applicable.


There is no funding. The authors declare that no financial conflict of interest exists.

Availability of data and materials

Not applicable.

Authors’ contributions

YI and MT planned the study, searched and collected the literatures, and wrote the manuscript. YS wrote the manuscript. FS and MM discussed the contents of manuscript with YI and MT. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Department of Nephrology and Renal Replacement Therapy, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan


  1. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9 Suppl 12:16–23.Google Scholar
  2. Masakane I, Nakai S, Ogata S, Kimata N, Hanafusa N, Hamano T, et al. An overview of regular dialysis treatment in japan (As of 31 December 2013). Ther Apher Dial. 2015;19:540–74.View ArticlePubMedGoogle Scholar
  3. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–17.View ArticlePubMedGoogle Scholar
  4. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.View ArticlePubMedGoogle Scholar
  5. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.View ArticlePubMedGoogle Scholar
  6. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108:1831–8.View ArticlePubMedGoogle Scholar
  7. Greenblatt DJ, Koch-Weser J. Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program. JAMA. 1973;225:40–3.View ArticlePubMedGoogle Scholar
  8. Kushner FG, Hand M, Smith Jr SC, King 3rd SB, Anderson JL, Antman EM, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 Guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120:2271–306.View ArticlePubMedGoogle Scholar
  9. Lumb G, Newberne P, Rust JH, Wagner B. Effects in animals of chronic administration of spironolactone—a review. J Environ Pathol Toxicol. 1978;1:641–60.PubMedGoogle Scholar
  10. Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail. 1996;2:47–54.View ArticlePubMedGoogle Scholar
  11. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1995;76:1259–65.View ArticlePubMedGoogle Scholar
  12. Ponda MP, Hostetter TH. Aldosterone antagonism in chronic kidney disease. Clin J Am Soc Nephrol. 2006;1:668–77.View ArticlePubMedGoogle Scholar
  13. Laragh JH. Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles. Am J Med. 1973;55:261–74.View ArticlePubMedGoogle Scholar
  14. Tanabe A, Naruse M, Naruse K, Hase M, Yoshimoto T, Tanaka M, et al. Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension. Hypertens Res. 1997;20:85–90.View ArticlePubMedGoogle Scholar
  15. Coirini H, Magarinos AM, De Nicola AF, Rainbow TC, McEwen BS. Further studies of brain aldosterone binding sites employing new mineralocorticoid and glucocorticoid receptor markers in vitro. Brain Res. 1985;361:212–6.View ArticlePubMedGoogle Scholar
  16. Kornel L. Colocalization of 11 beta-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells. Am J Hypertens. 1994;7:100–3.PubMedGoogle Scholar
  17. Bonvalet JP, Alfaidy N, Farman N, Lombes M. Aldosterone: intracellular receptors in human heart. Eur Heart J. 1995;16(Suppl N):92–7.View ArticlePubMedGoogle Scholar
  18. Robert V, Silvestre JS, Charlemagne D, Sabri A, Trouve P, Wassef M, et al. Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension. 1995;26:971–8.View ArticlePubMedGoogle Scholar
  19. Delcayre C, Swynghedauw B. Molecular mechanisms of myocardial remodeling. The role of aldosterone. J Mol Cell Cardiol. 2002;34:1577–84.View ArticlePubMedGoogle Scholar
  20. Duprez D, De Buyzere M, Rietzschel ER, Clement DL. Aldosterone and vascular damage. Curr Hypertens Rep. 2000;2:327–34.View ArticlePubMedGoogle Scholar
  21. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101:594–7.View ArticlePubMedGoogle Scholar
  22. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart : role of oxidative stress. Am J Pathol. 2002;161:1773–81.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology. 2002;143:4828–36.View ArticlePubMedGoogle Scholar
  24. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension. 2006;47:656–64.View ArticlePubMedGoogle Scholar
  25. Struthers AD, MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res. 2004;61:663–70.View ArticlePubMedGoogle Scholar
  26. Fujita T. Aldosterone in salt-sensitive hypertension and metabolic syndrome. J Mol Med (Berl). 2008;86:729–34.View ArticleGoogle Scholar
  27. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res. 1990;67:1355–64.View ArticlePubMedGoogle Scholar
  28. Lombes M, Oblin ME, Gasc JM, Baulieu EE, Farman N, Bonvalet JP. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res. 1992;71:503–10.View ArticlePubMedGoogle Scholar
  29. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension. 2006;47:312–8.View ArticlePubMedGoogle Scholar
  30. Van Belle E, Bauters C, Wernert N, Hamon M, McFadden EP, Racadot A, et al. Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, and aldosterone antagonist. Cardiovasc Res. 1995;29:27–32.View ArticlePubMedGoogle Scholar
  31. Sawathiparnich P, Kumar S, Vaughan DE, Brown NJ. Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. J Clin Endocrinol Metab. 2002;87:448–52.View ArticlePubMedGoogle Scholar
  32. Dinh QN, Young MJ, Evans MA, Drummond GR, Sobey CG, Chrissobolis S. Aldosterone-induced oxidative stress and inflammation in the brain are mediated by the endothelial cell mineralocorticoid receptor. Brain Res. 2016;1637:146–53.View ArticlePubMedGoogle Scholar
  33. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med. 2007;13:189–97.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Nagata D, Takahashi M, Sawai K, Tagami T, Usui T, Shimatsu A, et al. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension. 2006;48:165–71.View ArticlePubMedGoogle Scholar
  35. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation. 2002;105:2212–6.View ArticlePubMedGoogle Scholar
  36. Takai S, Jin D, Muramatsu M, Kirimura K, Sakonjo H, Miyazaki M. Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension. 2005;46:1135–9.View ArticlePubMedGoogle Scholar
  37. Mueller KB, Bender SB, Hong K, Yang Y, Aronovitz M, Jaisser F, et al. Endothelial mineralocorticoid receptors differentially contribute to coronary and mesenteric vascular function without modulating blood pressure. Hypertension. 2015;66:988–97.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res. 2005;97:434–42.View ArticlePubMedGoogle Scholar
  39. Callera GE, Touyz RM, Tostes RC, Yogi A, He Y, Malkinson S, et al. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension. 2005;45:773–9.View ArticlePubMedGoogle Scholar
  40. Tatsumoto N, Yamada S, Tokumoto M, Eriguchi M, Noguchi H, Torisu K, et al. Spironolactone ameliorates arterial medial calcification in uremic rats: the role of mineralocorticoid receptor signaling in vascular calcification. Am J Physiol Renal Physiol. 2015;309:F967–79.PubMedGoogle Scholar
  41. Galmiche G, Pizard A, Gueret A, El Moghrabi S, Ouvrard-Pascaud A, Berger S, et al. Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness. Hypertension. 2014;63:520–6.View ArticlePubMedGoogle Scholar
  42. Papadimitriou M, Vyzantiadis A, Milionis A, Memmos D, Metaxas P. The effect of spironolactone in hypertensive patients on regular haemodialysis and after renal allotransplantation. Life Support Syst. 1983;1:197–205.PubMedGoogle Scholar
  43. Saudan P, Mach F, Perneger T, Schnetzler B, Stoermann C, Fumeaux Z, et al. Safety of low-dose spironolactone administration in chronic haemodialysis patients. Nephrol Dial Transplant. 2003;18:2359–63.View ArticlePubMedGoogle Scholar
  44. Hussain S, Dreyfus DE, Marcus RJ, Biederman RW, McGill RL. Is spironolactone safe for dialysis patients? Nephrol Dial Transplant. 2003;18:2364–8.View ArticlePubMedGoogle Scholar
  45. Gross E, Rothstein M, Dombek S, Juknis HI. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. Am J Kidney Dis. 2005;46:94–101.View ArticlePubMedGoogle Scholar
  46. Shavit L, Neykin D, Lifschitz M, Slotki I. Effect of eplerenone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric chronic hemodialysis patients - a pilot study. Clin Nephrol. 2011;76:388–95.View ArticlePubMedGoogle Scholar
  47. Walsh M, Manns B, Garg AX, Bueti J, Rabbat C, Smyth A, et al. The safety of eplerenone in hemodialysis patients: a noninferiority randomized controlled trial. Clin J Am Soc Nephrol. 2015;10:1602–8.View ArticlePubMedPubMed CentralGoogle Scholar
  48. Taheri S, Mortazavi M, Shahidi S, Pourmoghadas A, Garakyaraghi M, Seirafian S, et al. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi J Kidney Dis Transpl. 2009;20:392–7.PubMedGoogle Scholar
  49. McGill RL, Biederman RW, Getts RT, Hazlett SM, Sharma SB, Duran J, et al. Cardiac magnetic resonance imaging in hemodialysis patients. J Nephrol. 2009;22:367–72.PubMedGoogle Scholar
  50. Flevari P, Kalogeropoulou S, Drakou A, Leftheriotis D, Panou F, Lekakis J, et al. Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients. J Hypertens. 2013;31:1239–44.View ArticlePubMedGoogle Scholar
  51. Feniman-De-Stefano GM, Zanati-Basan SG, De Stefano LM, Xavier PS, Castro AD, Caramori JC, et al. Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients. Ther Adv Cardiovasc Dis. 2015;9:158–67.View ArticlePubMedGoogle Scholar
  52. Matsumoto Y, Mori Y, Kageyama S, Arihara K, Sugiyama T, Ohmura H, et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol. 2014;63:528–36.View ArticlePubMedGoogle Scholar
  53. Matsumoto Y, Kageyama S, Yakushigawa T, Arihara K, Sugiyama T, Mori Y, et al. Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients. Cardiology. 2009;114:32–8.View ArticlePubMedGoogle Scholar
  54. Lin C, Zhang Q, Zhang H, Lin A. Long-term effects of low-dose spironolactone on chronic dialysis patients: a randomized placebo-controlled study. J Clin Hypertens (Greenwich). 2016;18:121–8.View ArticleGoogle Scholar
  55. Nitta K, Akiba T, Nihei H. Aldosterone blockade and vascular calcification in hemodialysis patients. Am J Med. 2003;115:250.View ArticlePubMedGoogle Scholar
  56. Vukusich A, Kunstmann S, Varela C, Gainza D, Bravo S, Sepulveda D, et al. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin J Am Soc Nephrol. 2010;5:1380–7.View ArticlePubMedPubMed CentralGoogle Scholar
  57. Hausmann MJ, Liel-Cohen N. Aldactone therapy in a peritoneal dialysis patient with decreased left ventricular function. Nephrol Dial Transplant. 2002;17:2035–6.View ArticlePubMedGoogle Scholar
  58. Taheri S, Mortazavi M, Pourmoghadas A, Seyrafian S, Alipour Z, Karimi S. A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis. Saudi J Kidney Dis Transpl. 2012;23:507–12.PubMedGoogle Scholar
  59. Yongsiri S, Thammakumpee J, Prongnamchai S, Tengpraettanakorn P, Chueansuwan R, Tangjaturonrasme S, et al. Randomized, double-blind, placebo-controlled trial of spironolactone for hypokalemia in continuous ambulatory peritoneal dialysis patients. Ther Apher Dial. 2015;19:81–6.View ArticlePubMedGoogle Scholar
  60. Ito Y, Mizuno M, Suzuki Y, Tamai H, Hiramatsu T, Ohashi H, et al. Long-term effects of spironolactone in peritoneal dialysis patients. J Am Soc Nephrol. 2014;25:1094–102.View ArticlePubMedGoogle Scholar
  61. Devuyst O, Margetts PJ, Topley N. The pathophysiology of the peritoneal membrane. J Am Soc Nephrol. 2010;21:1077–85.View ArticlePubMedGoogle Scholar
  62. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int. 2004;66:408–18.View ArticlePubMedGoogle Scholar
  63. De Vriese AS, Flyvbjerg A, Mortier S, Tilton RG, Lameire NH. Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane. J Am Soc Nephrol. 2003;14:2109–18.View ArticlePubMedGoogle Scholar
  64. Davies SJ. Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int. 2004;66:2437–45.View ArticlePubMedGoogle Scholar
  65. Selgas R, Fernandez-Reyes MJ, Bosque E, Bajo MA, Borrego F, Jimenez C, et al. Functional longevity of the human peritoneum: how long is continuous peritoneal dialysis possible? Results of a prospective medium long-term study. Am J Kidney Dis. 1994;23:64–73.View ArticlePubMedGoogle Scholar
  66. del Peso G, Fernandez-Reyes MJ, Hevia C, Bajo MA, Castro MJ, Cirugeda A, et al. Factors influencing peritoneal transport parameters during the first year on peritoneal dialysis: peritonitis is the main factor. Nephrol Dial Transplant. 2005;20:1201–6.View ArticlePubMedGoogle Scholar
  67. Davies SJ, Bryan J, Phillips L, Russell GI. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant. 1996;11:498–506.View ArticlePubMedGoogle Scholar
  68. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol. 2002;13:470–9.PubMedGoogle Scholar
  69. Sawai A, Ito Y, Mizuno M, Suzuki Y, Toda S, Ito I, et al. Peritoneal macrophage infiltration is correlated with baseline peritoneal solute transport rate in peritoneal dialysis patients. Nephrol Dial Transplant. 2011;26:2322–32.View ArticlePubMedGoogle Scholar
  70. Nishimura H, Ito Y, Mizuno M, Tanaka A, Morita Y, Maruyama S, et al. Mineralocorticoid receptor blockade ameliorates peritoneal fibrosis in new rat peritonitis model. Am J Physiol Renal Physiol. 2008;294:F1084–93.View ArticlePubMedGoogle Scholar
  71. Zhang L, Hao JB, Ren LS, Ding JL, Hao LR. The aldosterone receptor antagonist spironolactone prevents peritoneal inflammation and fibrosis. Lab Invest. 2014;94:839–50.View ArticlePubMedGoogle Scholar
  72. Yelken B, Gorgulu N, Gursu M, Yazici H, Caliskan Y, Telci A, et al. Effects of spironolactone on residual renal function and peritoneal function in peritoneal dialysis patients. Adv Perit Dial. 2014;30:5–10.PubMedGoogle Scholar
  73. Vazquez-Rangel A, Soto V, Escalona M, Toledo RG, Castillo EA, Polanco Flores NA, et al. Spironolactone to prevent peritoneal fibrosis in peritoneal dialysis patients: a randomized controlled trial. Am J Kidney Dis. 2014;63:1072–4.View ArticlePubMedGoogle Scholar


© The Author(s) 2016